Powered 500 · 2026POWEREDS. 089 of 500
After co-founding Kite Pharma and selling it to Gilead for $11.9 billion, Belldegrun is now building Allogene Therapeutics to make CAR T cell therapy available off-the-shelf — eliminating the patient-by-patient manufacturing that limits who can access it.
Arie Belldegrun is the Founder and Executive Chairman of Allogene Therapeutics, a clinical-stage biotechnology company pioneering allogeneic (off-the-shelf) CAR T cell therapy for cancer.
Belldegrun previously co-founded Kite Pharma, which developed the groundbreaking CAR T cell therapy Yescarta for the treatment of certain types of lymphoma. Kite Pharma was acquired by Gilead Sciences in 2017 for $11.9 billion, one of the largest biotech acquisitions in history. A urologic oncologist by training, Belldegrun served as Professor and Chief of Urologic Oncology at UCLA before his entrepreneurial career. With Allogene, he is working to make cell therapy more accessible by developing treatments that can be manufactured in advance and given to any patient, rather than requiring individualized production from each patient's own cells. His serial biotech entrepreneurship-from academic medicine to founding two transformative cancer therapy companies-represents exceptional translation of scientific innovation into clinical and commercial impact.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
